Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies

This study has been completed.
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota Identifier:
First received: August 12, 2010
Last updated: January 21, 2016
Last verified: January 2016

August 12, 2010
January 21, 2016
August 2010
August 2015   (Final data collection date for primary outcome measure)
Objective Response Rate [ Time Frame: Month 2 Post Infusion ]
The proportion of patients with an objective response rate (Partial Response +Complete Response) at 2 months post haploidentical NK cell infusion in patient with refractory/relapsed NHL or chronic lymphocytic leukemia (CLL).
Same as current
Complete list of historical versions of study NCT01181258 on Archive Site
  • Serious Adverse Events [ Time Frame: Day 1 through Month 12 ]
    Number of serious adverse events that occur during study. Adverse event collection for the purposes of this study will focus on targeted adverse events and unexpected adverse events at specific time points in relation to the NK cell infusion and post infusion IL2 injections.
  • Time to Disease Progression [ Time Frame: Day 1 through Month 12 ]
    Cumulative incidence will be used to determine time to disease progression.
  • Patients with Expansion of NK Cells [ Time Frame: Day 14 ]
    Number of patients who experience in vivo expansion of allogeneic donor natural killer (NK) cells.
Same as current
Not Provided
Not Provided
Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies
Lymphodepleting Chemotherapy With Rituximab and Allogeneic Natural Killer Cells for Patients With Refractory Lymphoid Malignancies (MT2009-15)
In this study the investigators investigate a cell therapy strategy that could harness allogeneic effectors that can potentially mediate anti-lymphoma effect. The investigators have designed a novel lymphodepleting conditioning regimen followed by infusion of donor-derived natural killer (NK) cells and interleukin-2 (IL-2) for patients with refractory lymphoid malignancies.

This is a single center phase II trial designated to expand donor NK cells and induce remissions in patients with refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) using chemotherapy followed by haploidentical NK cells and IL2.

Primary Objective is to evaluate the objective response rate (PR+CR) at 2 months post haploidentical NK cell infusion in patients with refractory Non Hodgkin's Lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

Secondary Objective is to 1) evaluate the safety and tolerability of lymphodepleting chemotherapy, rituximab, and methylprednisone as determined by incidence of serious adverse events; 2) evaluate in vivo expansion of allogeneic donor NK cells at day 14; 3) determine time to progression

Exploratory Objective is to 1) correlate clinical response with frequencies of peripheral blood T reg cells after chemotherapy; 2) correlate clinical response with donor KIR-B-content score determined by genotype; 3) monitor phenotypic and functional characteristics of natural killer cells and regulatory T cells in vivo; 4) correlate clinical response with donor FcR polymorphism.

  • Pre-NK cell infusion chemotherapeutic regimen consist of 1) Rituximab 375mg/m2 IV weekly x 4, start day -7; 2) Fludarabine 25 mg/m2 IV day -6 through day -2; 3) Cyclophosphamide 60mg/kg IV day -5; 4) Methylprednisolone 1 mg/kg day -2 through day +9.
  • NK cell infusion using IL2 activated donor NK cells 1.5 to 8 x 107 cells/kg IV day 0
  • IL2 SC 9 million IU every other day x 6 doses over 2 weeks begin 1 to 24 hours after NK cell infusion. If weight < 45 kilograms, give IL-2 at 5 million units/m2 on same schedule

Accrual Goal: Up to 17 patients will be enrolled

Phase 2
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Non-Hodgkin Lymphoma
  • Chronic Lymphocytic Leukemia
  • Drug: Rituximab
    375 mg/m^2 administered intravenously (IV) weekly * 4, (day -7, -1, +6, +13) pre-infusion with natural killer cells (NK)
    Other Names:
    • Rituxan
    • MabThera
  • Biological: Interleukin-2
    subcutaneously administered 9 million international units (IU) every other day * 6 doses over 2 weeks begin 1 to 24 hours after NK cell infusion. If weight < 45 kilograms, give IL-2 at 5 million units/m2 on same schedule.
    Other Name: IL-2
  • Biological: Natural killer cells
    administered intravenously 1.5 to 8 * 10^7 cells/kg on Day 0 (day of NK cell infusion)
    Other Name: NK cells
  • Drug: Cyclophosphamide
    60 mg/kg administered intravenously (IV) for 2 hours on day -5 after Fludarabine.
    Other Name: Cytoxan
  • Drug: Methylprednisolone
    1 mg/kg on Days -2 through +9 as an intravenous (IV) infusion.
    Other Name: Medrol
  • Drug: Fludarabine
    25 mg/m^2/day administered as a 1 hour IV infusion once a day for 5 doses (day -6 through day -2).
    Other Name: Fludara
Experimental: Patients Receiving NK Cell Infusion
Non-Myeloablative Conditioning Using Rituximab, Fludarabine, Cyclophosphamide and Methylprednisolone followed by Interleukin 2-activated Allogeneic Natural Killer Cells infusion for Patients with Refractory NHL and CLL
  • Drug: Rituximab
  • Biological: Interleukin-2
  • Biological: Natural killer cells
  • Drug: Cyclophosphamide
  • Drug: Methylprednisolone
  • Drug: Fludarabine
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
August 2015
August 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients of any age with diagnosis of:

    • Relapsed/refractory lymphoma (B cell non-Hodgkin) who have lack of objective response to at least two prior chemotherapy regimens
    • Relapsed chronic lymphocytic leukemia with high risk features: lack of objective response or relapse within 6 months following nucleoside-analogue based chemotherapy regimen or patients with 17p deletion CLL who lacked objective response to at least 1 preceding chemotherapy regimen
  • Available related HLA haploidentical NK cell donor by at least Class I serologic typing at the A&B locus (age 12-75 years)
  • Karnofsky > 70% for patients 16 years and older and Lansky play score > 50 for patients under 16 years of age
  • Measurable disease based on modified Response Evaluation Criteria in Solid Tumors (RECIST)
  • Have acceptable organ function as defined within 28 days of enrollment:

    • Hematologic: platelets ≥ 80,000 x 10^9/L; hemoglobin ≥ 9 g/dL, unsupported by transfusions within 7 days; absolute neutrophile count (ANC) ≥ 1000 x 10^9/L, unsupported by Granulocyte colony-stimulating factor (G-CSF) or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) for 10 days or Neulasta for 21 days - the hematologic requirements are waived for patients with inadequate counts due to known bone marrow involvement by disease who are otherwise eligible
    • Renal: calculated glomerular filtration rate (GFR) > 50 ml/min
    • Hepatic: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 5 x upper limit of normal and total bilirubin ≤3 mg/dl - hepatic requirements are waived for patients with known disease involvement in the liver if otherwise eligible
    • Pulmonary function: >40% corrected Carbon Monoxide Diffusing Capacity (DLCO) and Forced expiratory volume in one second (FEV1) (oxygen saturation [>92%] can be used in child where pulmonary function tests (PFT's) cannot be obtained)
    • Cardiac: no symptoms of uncontrolled cardiac disease, left ventricular ejection fraction ≥ 40%
  • Able to be off prednisone or other immunosuppressive medications for at least 3 day prior to Day 0 (excluding denileukin diftitox pre-medications)
  • Sexually active women of childbearing potential must agree to use adequate contraception (diaphragm, birth control pills, injections, intrauterine device [IUD], surgical sterilization, subcutaneous implants, or abstinence, etc.) for the duration of treatment.
  • Voluntary written consent

Exclusion Criteria:

  • Pregnant or lactating. The agents used in this study may be teratogenic to a fetus and there is no information on the excretion of agents into breast milk. All females of childbearing potential must have a blood test or urine study within 14 days prior to enrollment to rule out pregnancy. Women of childbearing age must use appropriate contraceptive method.
  • Active central nervous system (CNS) lymphoma/leukemia - Patients with prior CNS involvement are eligible provided that it has been treated and is in remission.
  • Active serious infection (pulmonary infiltrates or lesions are allowed only after the appropriate diagnostic testing is negative for infection or appropriate therapy was initiated for probable infection)
  • Pleural effusion large enough to be detectable on chest x-ray (CXR)
  • Evidence of human immunodeficiency virus (HIV) infection or known HIV positive serology
  • Active concurrent malignancy (except skin cancer)
  • Epstein-Barr virus (EBV) post-transplant lymphoproliferative disorder
  • Positive HBsAg. If HBcAb is positive, Hepatitis B DNA by PCR will be evaluated. Positive anti HBcAb with an undetectable viral load does not exclude the patient.
  • Any investigational therapy in the past 30 days
  • Patients following allogeneic stem cell transplantation are eligible in the absence of graft versus host disease and are off immunosuppression for at least 30 days
  • Known allergy to any of the study agents
Sexes Eligible for Study: All
Child, Adult, Senior
Contact information is only displayed when the study is recruiting subjects
United States
MT2009-15 ( Other Identifier: Blood and Marrow Transplantation Program )
1002M77545 ( Other Identifier: IRB, University of Minnesota )
Not Provided
Not Provided
Not Provided
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Not Provided
Principal Investigator: Veronika Bachanova, MD Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
January 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP